RT Journal Article
SR Electronic
T1 Potential involvement of monoamine oxidase activity in SARS-COV2 infection and delirium onset
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.16.20128660
DO 10.1101/2020.06.16.20128660
A1 Cuperlovic-Culf, Miroslava
A1 Cunningham, Emma L.
A1 Surendra, Anu
A1 Pan, Xiaobei
A1 Bennett, Steffany A.L.
A1 Jung, Mijin
A1 McGuiness, Bernadette
A1 Passmore, Anthony Peter
A1 McAuley, Danny
A1 Beverland, David
A1 Green, Brian D.
YR 2020
UL http://medrxiv.org/content/early/2020/06/28/2020.06.16.20128660.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a range of extra-respiratory signs and symptoms. One such manifestation is delirium, an acute confusional state occurring in 60-70% of severe SARS-CoV-2 cases. Delirium is also a common clinical syndrome following planned orthopedic surgery. This investigation initially explored the underlying role of metabolism in delirium-susceptibility in this setting. Metabolomics profiles of cerebrospinal fluid (CSF) and blood taken prior to surgery found significant concentration differences of several amino acids, acylcarnitines and polyamines were observed in delirium-prone patients. Phenethylamine (PEA) concentrations in delirium-prone patients was significantly lower in CSF than in blood, whilst in age- and gender-matched controls the opposite was observed (adjusted p values: 1.8×10−6 (control) and 1.788×10−10 (delirium)). PEA is metabolised by monoamine oxidase B (MAOB), a putative enzyme target for the treatment of Alzheimer’s disease, Parkinson’s disease and depression. Our computational structural comparisons of MAOB and angiotensin converting enzyme (ACE) 2 found high similarity, specifically within the SARS-CoV-2 spike protein. MAOB structural alignment to ACE2 was 51% overall, but this was over 95% in the ACE2-spike protein binding region. Thus, it is possible that the spike protein interacts with MAOB on a molecular level. A previously published metabolomic dataset of control subjects and patients with either mild or severe COVID-19 was then analysed. Major concentration differences in some metabolites attributed to altered MAO activity were detected. Therefore, our hypothesis is that the SARS-CoV-2 influences MAOB activity, which is one potential cause for the many observed neurological and platelet based complications of SARS-CoV-2 infection. Further research is required to establish what effect MAOB inhibitors might have on these pathways. There is no evidence at present to support the withholding of MAOB inhibitors.Significance Statement Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a range of extra-respiratory signs and symptoms including delirium, anosmia, intravascular coagulation. Analysis of metabolomics differences in delirium-prone patients and in severe cases of SARS-CoV2 infection indicate possibly significant role for monoamine oxidase B (MAOB). Changes in activity of MAOB have been shown in other conditions to cause range of symptoms observed in SARS-CoV2 infection. Computational structural analysis presented here demonstrations significant similarity between MAOB and ACE2 protein binding region leading to a hypothesis that SARS-CoV-2 spike protein affects MAOB activity during the infection. This proposition is possibly of significance for both diagnosis of high-risk subjects prior to infection as well as novel avenues for the development of treatment and prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAlzheimers Research UK (Metabolomic Analyses funded by Network Centre Pump Priming Grant). Cohort Study Funded by: Siew Keok Chin Scholarship (Philanthropic Funding). Belfast Arthroplasty Research Trust and Belfast Trust Charitable Funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Office for Research Ethics Committee for Northern Ireland approved the study (REC ref: 10/NIR01/5).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests can be send to the authors.